Human recombinant protein Ubiquitin-K33R
Human Recombinant Ubiquitin-K33R
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P62979 |
---|---|
Concentration | 4 |
Calculated MW | 8.592 kDa |
Gene ID | 6233 |
---|---|
Gene Symbol | RPS27A |
Gene Source | Human |
Source | E. Coli |
Assay&Purity | RP-HPLC; ≥95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Format | Liquid |
Storage | -80°C; 4 mg/ml in 20 mM Tris, pH 7.5, 0.15 M NaCl and 10% glycerol. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Ubiquitin is a small polypeptide that can be conjugated via its C-terminus to amine groups of lysine residue on target proteins. This conjunction is referred to as monoubiquitylation. Additional ubiquitin moieties can be subsequently conjugated to this initial ubiquitin, utilizing any one of the seven lysine residues on the surface of ubiquitin. The formation of these ubiquitin chains is referred to as polyubiquitylation. This tag-free recombinant form of human ubiquitin is engineered to have a single substitution of arginine for lysine at position 33. Covalent attachment of ubiquitin to other proteins serves various functions, but its major role is to target cellular proteins for destruction. Cellular components that activate, transfer, remove, or simply recognize ubiquitin number in the hundreds, perhaps even in the thousands. In light of this complexity the ubiquitin pathway is ideal for a systems biology approach. Ubiquitin plays a very important role in regulated non-lysosomal ATP dependent protein degradation. The Ub-proteasome proteolytic pathway, which is a complex process, is implicated to be of great importance for regulating numerous cellular processes.
References
Pancre V.,et al.Eur. J. Immunol. 21:2735-2741(1991).
Adams S.M.,et al.Br. J. Cancer 65:65-71(1992).
Hillier L.W.,et al.Nature 434:724-731(2005).
Vladimirov S.N.,et al.Eur. J. Biochem. 239:144-149(1996).
Schlesinger D.H.,et al.Nature 255:423-424(1975).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.